[1]周心怡,孙 鑫,黄文凯,等.2021年中国人群可筛查癌症的疾病经济负担研究[J].卫生经济研究,2026,43(01):26-30,36.
　ZHOU Xinyi,SUN Xin,HUANG Wenkai,et al.Economic Burden of Screenable Cancers in the Chinese Population in 2021[J].Journal Press of Health Economics Research,2026,43(01):26-30,36.
点击复制

2021年中国人群可筛查癌症的疾病经济负担研究

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
43
期数:
2026年01期
页码:
26-30,36
栏目:
疾病负担
出版日期:
2026-01-06

文章信息/Info

Title:
Economic Burden of Screenable Cancers in the Chinese Population in 2021
作者:
周心怡1; 孙 鑫1; 黄文凯1; 蔡森瑶1; 邹苏阳1; 石菊芳1; 魏文强1
1.国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院，北京 100021
Author(s):
ZHOU Xinyi;  SUN Xin;  HUANG Wenkai;  CAI Senyao;  ZOU Suyang;  SHI Jufang;  WEI Wenqiang
National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
关键词:
癌症; 疾病经济负担; 间接经济负担; 筛查
Keywords:
cancer;  economic burden of disease;  indirect economic burden;  screening
分类号:
R19
文献标志码:
A
摘要:
目的：量化我国人群可筛查干预的8种常见癌症所致疾病经济负担，讨论筛查干预的可能影响。方法：基于多源公开数据，采用人力资本法结合伤残调整寿命年，测算我国人群可筛查干预的8种癌症所致间接经济负担；基于核心文献，延展简析对应的直接经济负担。结果：2021年，我国人群可筛查干预的8种癌症所致间接经济负担为7 685.22亿元，占所有癌种的75.76%，占同年GDP的0.67%；早亡所致间接经济负担为7 530.91亿元（97.99%），消化系统癌症（食管癌、胃癌、结直肠癌和肝癌）间接经济负担合计为4 581.83亿元，疫苗可防的癌症（肝癌和宫颈癌）间接经济负担为1 248.33亿元，女性乳腺癌和宫颈癌间接经济负担合计为548.20亿元，肺癌在单个癌种中所致间接经济负担最高（2 329.15亿元）；延展分析显示，2021年我国人群可筛查干预的8种癌症所致直接经济负担从42.68亿元至1 212.11亿元不等。结论：我国人群可筛查干预癌症所致经济负担特别是间接经济负担总量不容忽视，随着筛查技术进一步成熟、可及性持续提高，筛查有望产生更大效益。
Abstract:
Objective To quantify the economic burden of eight common screenable cancers in the Chinese population and discuss the potential impact of screening interventions. Methods Based on multiple publicly available data sources, a human capital method combined with disability-adjusted life years(DALY) was used to estimate the indirect economic burden caused by eight screenable cancers in China. The corresponding direct economic burden was further analyzed based on core literature. Results In 2021, the indirect economic burden caused by the eight screenable cancers in China reached 768.522 billion yuan, accounting for 75.76% of the total burden of all cancers and 0.67% of the GDP in the same year. Premature death contributed 753.091 billion yuan(97.99%) to this indirect burden. Digestive system cancers(esophageal, gastric, colorectal, and liver cancers) accounted for 458.183 billion yuan, vaccine-preventable cancers(liver and cervical cancers) accounted for 124.833 billion yuan, and female breast cancer and cervical cancer together accounted for 54.820 billion yuan. Lung cancer had the highest burden among individual cancer types, amounting to 232.915 billion yuan. The extended analysis indicated that the direct economic burden caused by the eight screenable cancers in the Chinese population in 2021 ranged from 4.268 billion to 121.211 billion yuan. Conclusion The total economic burden, particularly the indirect economic burden, caused by screenable cancers in China is substantial. As screening technologies advance and the access continues to improve, screening interventions hold the potential to generate greater benefits.

参考文献/References:

[1] Han B F, Zheng R S, Zeng H M, et al. Cancer incidence and mortality in China, 2022[J]. Journal of the National Cancer Center, 2024, 46(03): 221-231.
[2] 郑荣寿，陈茹，韩冰峰，等. 2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志，2024，46（03）：221-231.
[3] 柴培培，李岩，翟铁民，等.2022年中国卫生总费用核算结果与分析[J]. 卫生经济研究，2024，41（01）：14-19.
[4] Zhai T M, Goss J, Dmytraczenko T, et al. China's Health Expenditure projections to 2035: future frajectory and the estimated impact of reforms[J]. Health Affairs, 2019, 38(05): 835-843.
[5] Feng X, Zahed H, Onwuka J, et al. Cancer stage compared with mortality as end points in randomized clinical trials of cancer screening: a systematic review and Meta-Analysis[J]. Jama, 2024, 331(22): 1910-1917.
[6] Xia C F, Basu P, Kramer B S, et al. Cancer screening in China: a steep road from evidence to implementation[J]. The Lancet Public Health, 2023, 8(12): e996-e1005.
[7] Zhou X Y, Wang X, Cai S Y, et al. Indirect economic burden of cancer in populations in China, 2021: a measurement based on a human capital approach[J]. Journal of Cancer Policy, 2025, 46: 100648.
[8] Institute for Health Metrics and Evaluation. Global Burden of Disease Study 2021[EB/OL].(2024-05-16)[2024-11-25]. https://ghdx.healthdata.org/gbd-2021.
[9] International Labour Organization. "Labour Force Statistics database (LFS)" ILOSTAT[EB/OL].[2024-08-11]. https://ilostat.ilo.org/data/#.
[10] 中华人民共和国统计局. 中国统计年鉴2023[M].北京：中国统计出版社，2023.
[11] 北京市师范大学.中国居民收入分配调查数据库2018[EB/OL]. [2025-01-10]. https://bs.bnu.edu.cn/zgjmsrfpdcsjk/sjjs/.
[12] 中国财政年鉴编辑部. 中国财政年鉴2022[M].北京：中国财政杂志社，2023.
[13] 国务院人口普查办公室，国家统计局人口和就业统计司.中国2010年人口普查资料[M].北京：中国统计出版社，2012.
[14] 国务院第七次全国人口普查领导小组办公室. 中国人口普查年鉴2020[M]. 北京： 中国统计出版社有限公司，2022.
[15] 中华人民共和国国家发展和改革委员会. 数据概览：2020年就业相关数据[EB/OL]. （2021-04-07）[2025-01-12]. https：//www.ndrc.gov.cn/fggz/fgzy/jjsjgl/202104/t20210414_1272304.html.
[16] Liu C C, Shi J F, Wang H, et al. Population-level economic burden of lung cancer in China: provisional prevalence-based estimations, 2017-2030[J]. Chinese Journal of Cancer Research, 2021, 33(01): 79-92.
[17] Cao M D, Liu C C, Wang H, et al. The population-level economic burden of liver cancer in China, 2019-2030: prevalence-based estimations from a societal perspective[J]. Cost Effectiveness and Resource Allocation, 2022, 20(01): 1-11.
[18] Wang H, Li Y J, Lei L, et al. Estimating the economic burden of colorectal cancer in China, 2019-2030: a population-level prevalence-based analysis[J]. Cancer Medicine, 2023, 13(01): e6787.
[19] Cai Y, Chen W Q, Wang X X, et al. Contemporary trends on expenditure of hospital care on total cancer and its subtypes in China during 2008-2017[J]. Chinese Journal of Cancer Research, 2021, 33(05): 627-636.
[20] Jiang S, Wang Y T, Si L, et al. Incorporating productivity loss in health economic evaluations: a review of guidelines and practices worldwide for research agenda in China[J]. BMJ Glob Health, 2022, 7(08): e009777.
[21] Lei S Y, Zheng R S, Zhang S K, et al. Years lived with disability of cancer in China: findings from disability weights measurement with a focus on the effect of disease burden[J]. Science Bulletin, 2023, 68(13): 1430-1438.
[22] 李敏娟，魏文强. 以筛查为抓手,多维度合力推进食管癌防控工作[J]. 肿瘤预防与治疗，2021，34（07）：587-590.
[23] Chen R, Zheng R S, Zhang S W, et al. Patterns and trends in esophageal cancer incidence and mortality in China: an analysis based on cancer registry data[J]. J Natl Cancer Cent, 2023, 3(01): 21-27.
[24] Shi J F, Cao M M, Wang Y T, et al. Is it possible to halve the incidence of liver cancer in China by 2050?[J]. Int J Cancer, 2021, 148(05): 1051-1065.
[25] 赫捷，陈万青，沈洪兵，等.中国人群肝癌筛查指南（2022，北京）[J].中华肿瘤杂志，2022，44（08）：779-814.
[26] Xia C F, Xu X Q, Zhao X L, et al. Effectiveness and cost-effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study[J]. BMC Med, 2021, 19(01): 62.
[27] 国家疾病预防控制局.关于将人乳头瘤病毒疫苗纳入国家免疫规划有关工作事宜的通知[EB/OL]. （2025-10-30）[2025-12-10]. https：//www.ndcpa.gov.cn/jbkzzx/c100014/common/content/conte nt_1983714327087452160.html.
[28] Chen W Q, Xia C F, Zheng R S, et al. Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessment[J]. The Lancet Global Health, 2019, 7(02): e257-e269.
[29] Wei W Q, Chen Z F, He Y T, et al. Long-term follow-up of a community assignment, one-time endoscopic screening study of esophageal cancer in China[J]. Journal of Clinical Oncology, 2015, 33(17): 1951-1957.
[30] Chen R, Liu Y, Song G H, et al. Effectiveness of one-time endoscopic screening programme in prevention of upper gastrointestinal cancer in China: a multicentre population-based cohort study[J]. Gut, 2021, 70(02): 251-260.
[31] Chen H D, Lu B, Shi J F, et al. Effectiveness and cost-effectiveness of risk-adapted colorectal cancer screening: a randomized controlled trial and modeling analysis[J]. Mil Med Res, 2025, 12(01): 82.
[32] 王鑫，李燕婕，雷林，等.中国适龄女性乳腺癌筛查服务的可及性——筛查率及其构成分析[J].中华流行病学杂志，2023，44（08）：1302-1308.
[33] 石菊芳，曹梦迪，严鑫鑫，等.肝癌筛查在我国人群中的可及性：一项探索性分析[J].中华流行病学杂志，2022，43（06）：906-914.
[34] Li Y J, Wang X, Wu Y J, et al. Access to colorectal cancer screening in populations in China, 2020: a coverage-focused synthesis analysis[J]. Int J Cancer, 2024, 155(03): 558-568.

相似文献/References:

[1]于保荣,许 晴,刘 卓,等.新发传染病经济负担的方法学研究[J].卫生经济研究,2017,(07):25.
[2]王晓茹,李银山,王 瑶,等.宁南地区新农合大病患者医疗费用负担分析[J].卫生经济研究,2017,(10):30.
[3]于保荣,冯映雪,江陈庆,等.肿瘤疾病经济负担与健康保险政策研究[J].卫生经济研究,2018,(04):14.
[4]冷 瑶,李燕喃,邓 晶.我国中老年糖尿病患者的疾病经济负担分析[J].卫生经济研究,2018,(10):47.
　LENG Yao,LI Yan-nan,DENG Jing.Analysis of the Economic Burden of Diseases in Middle-aged and Elderly Patients with Diabetes in China[J].Journal Press of Health Economics Research,2018,(01):47.
[5]明星宇,杨 练,孙 群,等.四川省糖尿病疾病经济负担及影响因素分析[J].卫生经济研究,2019,(01):29.
　MING Xing-yu,YANG Lian,SUN Qun,et al.The Disease Economic Burden and Influence of Diabetes in Sichuan Province[J].Journal Press of Health Economics Research,2019,(01):29.
[6]董 辉,汤质如,严 训,等.安徽省恶性肿瘤治疗费用分析——基于“卫生费用核算体系2011”[J].卫生经济研究,2021,38(2):58.
　DONG Hui,TANG Zhi-ru,YAN Xun,et al.Analysis on Malignant Tumor Treatment Cost in Anhui Province——Based on the SHA 2011[J].Journal Press of Health Economics Research,2021,38(01):58.
[7]黎倩欣,周尚成,陈飘飘,等.深圳市糖尿病疾病经济负担研究[J].卫生经济研究,2021,38(3):63.
　LI Qian-xin,ZHOU Shang-cheng,CHEN Piao-piao,et al.Study on the Economic Burden of Diabetic Diseases in Shenzhen[J].Journal Press of Health Economics Research,2021,38(01):63.
[8]王佳卉,马增香.多囊卵巢综合征及其并发症的直接经济负担研究进展[J].卫生经济研究,2022,39(3):24.
　WANG Jia-hui,MA Zeng-xiang.Research Progress on Direct Economic Burden of Polycystic Ovary Syndrome and Its Complications[J].Journal Press of Health Economics Research,2022,39(01):24.
[9]李福明,夏 宇,魏 艳,等.晚期非小细胞肺癌初治患者的直接非医疗成本分析[J].卫生经济研究,2022,39(10):58.
　LI Fuming,XIA Yu,WEI Yan,et al.Analysis of Direct Non-medical Cost of Newly Treated Advanced Non-small Cell Lung Cancer Patients[J].Journal Press of Health Economics Research,2022,39(01):58.
[10]王 凡,胡晓洁,陈 宇,等.海南省心血管疾病经济负担研究[J].卫生经济研究,2022,39(11):73.
　WANG Fan,HU Xiaojie,CHEN Yu,et al.Study on the Economic Burden of Cardiovascular Disease in Hainan Province[J].Journal Press of Health Economics Research,2022,39(01):73.

更新日期/Last Update: 2026-01-06